Mutant p53 proteins: Between loss and gain of function

Citations Over TimeTop 18% of 2006 papers

Abstract

Cancer might result from both the aberrant activation of genes, whose physiological tuning is essential for the life of a normal cell, and the inactivation of tumor suppressor genes, whose main job is to preserve the integrity of cell genome. Among the latter, p53 is considered a key tumor suppressor gene that is inactivated mainly by missense mutations in half of human cancers. It is becoming increasingly clear that the resulting mutant p53 proteins gain oncogenic properties favoring the insurgence, the maintenance, and the spreading of malignant tumors. In this review, we mainly discuss the molecular mechanisms underlying gain of function of human tumor-derived p53 mutants, their impact on the chemoresistance and the prognosis of human tumors, with a special focus on head and neck cancers, and the perspectives of treating tumors through the manipulation of mutant p53 proteins.

Related Papers

• → Missense variant contribution to USP9X-female syndrome(2020)37 cited
• → InFUSing antisense oligonucleotides for treating ALS(2022)11 cited
• → De Novo and Bi-allelic Pathogenic Variants in NARS1 Cause Neurodevelopmental Delay Due to Toxic Gain-of-Function and Partial Loss-of-Function Effects (4714)(2021)7 cited
• → Cytoplasmic gain-of-function mutant p53 contributes to inflammation-associated cancer(2015)3 cited
• → Proactive functional classification of all possible missense single-nucleotide variants in KCNQ4(2022)17 cited